1. Lister TA, Rohatiner AZ (1982) The treatment of acute myelogenous leukemia in adults. Semin Hematol 19:172–192
2. Wolff RA (2007) Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J 13:175–184
3. Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl 1):5–13
4. Abbruzzese JL (2002) New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 95:941–945
5. Heinemann V, Hertel LW, Grindey GB et al (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycy tidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024– 4031
6. Ross DD, Chen SR, Cuddy DP (1990) Effects of 1-beta- D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Cancer Res 50:2658–2666
7. Ross DD, Cuddy DP (1994) Molecular effects of 2′,2′-difluorodeox ycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619–1630
8. Ruiz van Haperen V, Veerman G, Vermorken JB et al (1993) 2′,2′- Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46:762–766
9. Molina-Arcas M, Trigueros-Motos L, Casado FJ et al (2008) Physiological and pharmacological roles of nucleoside transporter proteins. Nucleosides Nucleotides Nucleic Acids 27:769–778
10. Griffith DA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153–181
11. Mackey JR, Mani RS, Selner M et al (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349–4357
12. Gati WP, Paterson AR, Larratt LM et al (1997) Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90:346–353
13. Breistol K, Balzarini J, Sandvold ML et al (1999) Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 59:2944–2949
14. Bergman AM, Kuiper CM, Voorn DA et al (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67:503–511
15. Dueland S, Aamdal S, Lind MJ et al (2008) Intravenous administration of CP-4055 (ELACYTtrade mark) in patients with solid tumours. A phase I study. Acta Oncol 48:137–145
16. Brouwer M, Smets LA, Jongsma AP (1983) Isolation and characterization of subclones of L1210 murine leukemia with different sensitivities to various cytotoxic agents. Cancer Res 43:2884–2888
17. Lacaze N, Gombaud-Saintonge G, Lanotte M (1983) Conditions controlling long-term proliferation of Brown Norway rat promyelo- cytic leukemia in vitro: primary growth stimulation by microenvi- ronment and establishment of an autonomous Brown Norway ‘leukemic stem cell line’. Leuk Res 7:145–154
18. Lu Y, Han J, Scanlon KJ (1988) Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem 263:4891–4894
19. Ruiz van Haperen V, Veerman G, Eriksson S et al (1994) Development and molecular characterization of a 2′,2′-difluorodeox ycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54:4138–4143
20. Bergman AM, Eijk PP, Ruiz van Haperen V et al (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65:9510–9516
21. Smid K, Bergman AM, Eijk PP et al (2006) Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 25:1001–1007
22. Balzarini J, Schols D, Neyts J et al (1991) Alpha-(1-3)- and alpha- (1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother 35:410–416
23. Bergman AM, Pinedo HM, Jongsma AP et al (1999) Decreased resistance to gemcitabine (2′,2′-difluorodeoxycytidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57:397–406
24. Skehan P, Storeng R, Scudiero D et al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
25. Keepers YP, Pizao PE, Peters GJ et al (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27:897–900
26. Peters GJ, Wets M, Keepers YP et al (1993) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54:450–455
27. Monks A, Scudiero D, Skehan P et al (1991) Feasibility of a high- flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757–766
28. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823
29. Ruiz van Haperen V, Veerman G, Braakhuis BJ et al (1993) Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 29A:2132–2137
30. Fichtner I, Slisow W, Gill J et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298–307